Feedback

Efficacy and safety of glycyrrhizic acid preparation treating comorbid liver injury in COVID-19: A systematic review

Affiliation
Department of Respiratory Medicine ,Hospital of Chengdu University of Traditional Chinese Medicine ,Chengdu ,China
Liu, Xu;
Affiliation
Department of Respiratory Medicine ,Hospital of Chengdu University of Traditional Chinese Medicine ,Chengdu ,China
Tian, Xia;
Affiliation
Department of Respiratory Medicine ,Hospital of Chengdu University of Traditional Chinese Medicine ,Chengdu ,China
Ma, Zhipeng;
Affiliation
Department of Respiratory Medicine ,Hospital of Chengdu University of Traditional Chinese Medicine ,Chengdu ,China
Chen, Jiali;
Affiliation
Department of Respiratory Medicine ,Hospital of Chengdu University of Traditional Chinese Medicine ,Chengdu ,China
Huang, Qingsong;
Affiliation
Department of Critical Care Medicine ,Hospital of Chengdu University of Traditional Chinese Medicine ,Chengdu ,China
Gao, Peiyang;
Affiliation
Department of Respiratory Medicine ,Hospital of Chengdu University of Traditional Chinese Medicine ,Chengdu ,China
Zhang, Chuantao

Background: No specific drug for COVID-19 has been found, and many studies have found that different degrees of liver injury often occurred after infection with COVID-19. Glycyrrhizic acid preparation (GAP) has been frequently used clinically, often combined with conventional treatments such as antiviral therapy, to improve the prognosis of COVID-19 and patients’ liver function. Aims: To critically review and analyze clinical evidence on the efficacy and safety of GAP in the treatment of COVID-19 alone and COVID-19 with comorbid liver injury. Methods: A systematic literature review was performed following a sensitive searching strategy that examines all articles published in “WHO COVID-19 Research Database,” “Cochrane Library,” “VIP,” “CNKI,” “Wanfang,” and “CBM” from 2020 to July 2022. Articles were evaluated by peer reviewers and used Joanna Briggs Institute (JBI) critical appraisal tools to complete the assessment of the risk of bias. Results: Ten clinical studies were finally included, involving 598 patients with COVID-19, of whom 189 were confirmed to be with comorbid liver injury. The main GAPs used are diammonium glycyrrhizinate and magnesium isoglycyrrhizinate, which have shown efficacy in improving liver function, inhibiting inflammation, and enhancing immunity. We are still seeking more related research. Conclusion: Glycyrrhizic acid preparations (mainly diammonium glycyrrhizinate and magnesium isoglycyrrhizinate) have a considerable clinical effect on improving liver function in patients with COVID-19 alone or with comorbid liver injury. Further studies on the use of GAP in the treatment of COVID-19 with comorbid liver injury and its mechanism are still needed. Systematic Review Registration : [ www.crd.york.ac.uk/prospero ], identifier [CRD42021234647].

Cite

Citation style:
Could not load citation form.

Rights

License Holder: Copyright © 2022 Liu, Tian, Ma, Chen, Huang, Gao and Zhang.

Use and reproduction: